Premium
Self‐Assembling PCL‐Based Nanoparticles as PTX Solubility Enhancer Excipients
Author(s) -
Capasso Palmiero Umberto,
Morosi Lavinia,
Lupi Monica,
Ponzo Marianna,
Frapolli Roberta,
Zucchetti Massimo,
Ubezio Paolo,
Morbidelli Massimo,
D'Incalci Maurizio,
Bello Ezia,
Moscatelli Davide
Publication year - 2018
Publication title -
macromolecular bioscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.924
H-Index - 105
eISSN - 1616-5195
pISSN - 1616-5187
DOI - 10.1002/mabi.201800164
Subject(s) - paclitaxel , chemistry , amphiphile , copolymer , solubility , drug , nanoparticle , nanotechnology , polymerization , combinatorial chemistry , drug carrier , drug delivery , materials science , pharmacology , organic chemistry , polymer , surgery , medicine , chemotherapy
The advent of nanotechnology in medicine has allowed to eliminate the toxic excipients that are often necessary to formulate lipophilic drugs in clinics. An example is paclitaxel, one of the most important chemotherapeutic drugs developed so far, where the Cremophor EL has been eliminated in the Genexol and Abraxane formulations. However, the complex procedures to synthesize these formulations hamper their cost‐effective use and, in turn, their distribution among the patient population. For this reason, a simplified method to formulate this drug directly at the bed of the patient has been adopted. It requires only the use of a syringe and it starts from a native dry amphiphilic biodegradable and biocompatible block‐copolymer obtained via the combination of the reversible addition–fragmentation chain transfer polymerization and ring‐opening polymerization. In this way, a novel paclitaxel formulation with the same drug pharmacological properties, but without the use of the Cremophor EL, can be produced. In addition, as long as these nanoparticles are engineered to act as solubility enhancers, a lower burden for its approval from the pharmaceutical regulatory agencies is also expected.